These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34161969)

  • 1. Impact of a Nurse-Driven Heparin Monitoring Protocol for Ventricular Assist Devices.
    Gannon M; Simone PB
    AACN Adv Crit Care; 2021 Jun; 32(2):146-151. PubMed ID: 34161969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Implementation of an Anti-Factor Xa Heparin Monitoring Protocol.
    Williams-Norwood T; Caswell M; Milner B; Vescera JC; Prymicz K; Ciszak AG; Ingle C; Lacey C; Stavrou EX
    AACN Adv Crit Care; 2020 Jun; 31(2):129-137. PubMed ID: 32526007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
    Adatya S; Uriel N; Yarmohammadi H; Holley CT; Feng A; Roy SS; Reding MT; John R; Eckman P; Zantek ND
    JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of protocol guided heparin anticoagulation in patients with the TandemHeart percutaneous ventricular assist device.
    Lee Y; Weeks PA
    ASAIO J; 2015; 61(2):207-8. PubMed ID: 25423119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy.
    Slaughter MS; Naka Y; John R; Boyle A; Conte JV; Russell SD; Aaronson KD; Sundareswaran KS; Farrar DJ; Pagani FD
    J Heart Lung Transplant; 2010 Jun; 29(6):616-24. PubMed ID: 20400335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding Risks in Patients on Percutaneous Ventricular Assist Devices Receiving Two Different Dextrose Concentrations of Heparinized Purge Solution: A Case Series.
    Dietrich JN; Kazmi H
    J Pharm Pract; 2019 Aug; 32(4):464-469. PubMed ID: 29439593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coagulation factor abnormalities related to discordance between anti-factor Xa and activated partial thromboplastin time in patients supported with continuous-flow left ventricular assist devices.
    Adatya S; Sunny R; Fitzpatrick MJ; Colvin M; Thennapan T; John R; Dodge Zantek N; Pritzker M; Eckman P; Uriel N
    J Heart Lung Transplant; 2016 Nov; 35(11):1311-1320. PubMed ID: 27836023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing an Anti-Xa-Based Anticoagulation Protocol for Patients with Percutaneous Ventricular Assist Devices.
    Sieg A; Mardis BA; Mardis CR; Huber MR; New JP; Meadows HB; Cook JL; Toole JM; Uber WE
    ASAIO J; 2015; 61(5):502-8. PubMed ID: 26273933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of a Percutaneously Inserted Ventricular Support Device Purge Solution Heparin 25 U/mL.
    Jiang C; Stuart M; Makowski C; Jennings DL; To L
    Ann Pharmacother; 2021 Feb; 55(2):174-180. PubMed ID: 32741200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective anticoagulation for a percutaneous ventricular assist device using a heparin-based purge solution.
    Jennings DL; Nemerovski CW; Kalus JS
    Ann Pharmacother; 2013 Oct; 47(10):1364-7. PubMed ID: 24259702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulation Management for Impella Percutaneous Ventricular Assist Devices: An Analysis of a Single-Center Experience.
    Wood E; Hayes C; Hart A
    Ann Pharmacother; 2020 Nov; 54(11):1073-1082. PubMed ID: 32410456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An anticoagulation protocol for use after congenital cardiac surgery.
    Nair AG; Oladunjoye OO; Trenor CC; LaRonde M; van den Bosch SJ; Sleeper LA; VanderPluym C; Emani SM; Kheir JN
    J Thorac Cardiovasc Surg; 2018 Jul; 156(1):343-352.e4. PubMed ID: 29706371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous low molecular weight heparin for management of anticoagulation in infants on excor ventricular assist device.
    Ghez O; Liesner R; Karimova A; Ng C; Goldman A; van Doorn C
    ASAIO J; 2006; 52(6):705-7. PubMed ID: 17117062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
    Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
    Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
    Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
    J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal dosing of subcutaneous unfractionated heparin for the treatment of deep vein thrombosis.
    Kearon C; Harrison L; Crowther M; Ginsberg JS
    Thromb Res; 2000 Mar; 97(6):395-403. PubMed ID: 10704648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Argatroban as a primary or secondary postoperative anticoagulant in patients implanted with ventricular assist devices.
    Samuels LE; Kohout J; Casanova-Ghosh E; Hagan K; Garwood P; Ferdinand F; Goldman SM
    Ann Thorac Surg; 2008 May; 85(5):1651-5. PubMed ID: 18442558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Anticoagulation with Impella® Percutaneous Ventricular Assist Devices and Review of New Literature.
    Succar L; Sulaica EM; Donahue KR; Wanat MA
    J Thromb Thrombolysis; 2019 Aug; 48(2):284-291. PubMed ID: 30877619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
    Belk KW; Laposata M; Craver C
    J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.